GSK Paxil PTSD Approval Would Give Agent Widest Range Of SSRI Indications
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Approval of GlaxoSmithKline’s pending Paxil application for post-traumatic stress disorder would give the selective serotonin reuptake inhibitor the broadest range of indications among products in the class.